Sign in or Register   Sign in or Register
  |  

Mouse Anti-CD40 Recombinant Antibody (CBFYC-1296) (CBMAB-C1354-FY)

This product is mouse antibody that recognizes CD40. The antibody CBFYC-1296 can be used for immunoassay techniques such as: ELISA, FC, IHC, WB.
See all CD40 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBFYC-1296
Antibody Isotype
IgG2
Application
ELISA, FC, IHC, WB

Basic Information

Immunogen
Recombinant protein corresponding to human CD40
Specificity
Human
Antibody Isotype
IgG2
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Lyophilized
Buffer
PBS
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
CD40 Molecule
Introduction
CD40 (CD40 Molecule) is a Protein Coding gene. Diseases associated with CD40 include Immunodeficiency With Hyper-Igm, Type 3 and Cd40 Ligand Deficiency. Among its related pathways are NLR Proteins and Cytokine Signaling in Immune system. Gene Ontology (GO) annotations related to this gene include enzyme binding and receptor activity. An important paralog of this gene is TNFRSF11A.
Entrez Gene ID
UniProt ID
Alternative Names
CD40 Molecule; CD40 Molecule, TNF Receptor Superfamily Member 5; CD40L Receptor; TNFRSF5; CDW40; Bp50; Tumor Necrosis Factor Receptor Superfamily, Member 5
Function
Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973).
Costimulates T-cell proliferation and cytokine production (PubMed:8617933).
Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933).
Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973).
Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037).
Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037).
Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity).
Involved in immunoglobulin class switching (By similarity).
CD40 ligand, soluble form: Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling.
Biological Process
Activation of JUN kinase activity Source: UniProtKB
B cell differentiation Source: Ensembl
B cell proliferation Source: UniProtKB
CD40 signaling pathway Source: UniProtKB
Inflammatory response Source: UniProtKB
Integrin-mediated signaling pathway Source: UniProtKB
Isotype switching Source: UniProtKB
Leukocyte cell-cell adhesion Source: UniProtKB
Negative regulation of apoptotic process Source: UniProtKB
Platelet activation Source: UniProtKB
Positive regulation of endothelial cell apoptotic process Source: BHF-UCL
Positive regulation of interleukin-10 production Source: UniProtKB
Positive regulation of interleukin-12 production Source: UniProtKB
Positive regulation of interleukin-4 production Source: UniProtKB
Positive regulation of NF-kappaB transcription factor activity Source: UniProtKB
Positive regulation of T cell proliferation Source: UniProtKB
Regulation of immune response Source: Reactome
Regulation of immunoglobulin production Source: Ensembl
T cell costimulation Source: UniProtKB
Tumor necrosis factor-mediated signaling pathway Source: Reactome
Cellular Location
Cell membrane; Cell surface
CD40 ligand, soluble form: Secreted. Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and a matrix metalloproteinases (MMP) inhibitor-sensitive pathway.
Involvement in disease
Immunodeficiency with hyper-IgM, type 1 (HIGM1): Immunoglobulin isotype switch defect characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. Affected males present at an early age (usually within the first year of life) recurrent bacterial and opportunistic infections, including Pneumocystis carinii pneumonia and intractable diarrhea due to cryptosporidium infection. Despite substitution treatment with intravenous immunoglobulin, the overall prognosis is rather poor, with a death rate of about 10% before adolescence.
Topology
Cytoplasmic: 1-22
Helical: 23-46
Extracellular: 47-261
PTM
The soluble form derives from the membrane form by proteolytic processing.
N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40.
Not O-glycosylated.

Tang, T., Cheng, X., Truong, B., Sun, L., Yang, X., & Wang, H. (2021). Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacology & Therapeutics, 219, 107709.

Bullock, T. N. (2021). CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cellular & Molecular Immunology, 1-9.

Dakal, T. C., Dhabhai, B., Agarwal, D., Gupta, R., Nagda, G., Meena, A. R., ... & Sharma, A. (2020). Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders. Immunobiology, 225(2), 151899.

Richards, D. M., Sefrin, J. P., Gieffers, C., Hill, O., & Merz, C. (2020). Concepts for agonistic targeting of CD40 in immuno-oncology. Human vaccines & immunotherapeutics, 16(2), 377-387.

Lai, J. H., Luo, S. F., & Ho, L. J. (2019). Targeting the CD40-CD154 signaling pathway for treatment of autoimmune arthritis. Cells, 8(8), 927.

Schlievert, P. M., Cahill, M. P., Hostager, B. S., Brosnahan, A. J., Klingelhutz, A. J., Gourronc, F. A., ... & Leung, D. Y. (2019). Staphylococcal superantigens stimulate epithelial cells through CD40 to produce chemokines. MBio, 10(2), e00214-19.

Foster, A. E., Mahendravada, A., Shinners, N. P., Chang, W. C., Crisostomo, J., Lu, A., ... & Spencer, D. M. (2017). Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40. Molecular Therapy, 25(9), 2176-2188.

Chen, J., Song, Y., Bojadzic, D., Tamayo-Garcia, A., Landin, A. M., Blomberg, B. B., & Buchwald, P. (2017). Small-molecule inhibitors of the CD40–CD40L costimulatory protein–protein interaction. Journal of medicinal chemistry, 60(21), 8906-8922.

Aarts, S. A., Seijkens, T. T., Kusters, P. J., van der Pol, S. M., Zarzycka, B., Heijnen, P. D., ... & Lutgens, E. (2017). Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. Journal of neuroinflammation, 14(1), 1-14.

Chen, J., Li, J. H., Zhao, S. J., Wang, D. Y., Zhang, W. Z., & Liang, W. J. (2017). Clinical significance of costimulatory molecules CD40/CD40L and CD134/CD134L in coronary heart disease: a case-control study. Medicine, 96(32).

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-CD40 Recombinant Antibody (CBFYC-1296)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare